John F. Seymour

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.8K citations · Full text

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2018 · 1.6K citations · Full text

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elı́as Campo, Elaine S. Jaffe, James R. Cook et al. · Blood · 2022 · 1.4K citations · Full text

Immunology, Pathology, International Consensus Classification +22